1 / 11

Aarkstore - Multiple Myeloma (Kahlers Disease)

Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Multiple Myeloma (Kahler's Disease). Browse full report @ http://bit.ly/1BKX9dL

JustinSterling
Download Presentation

Aarkstore - Multiple Myeloma (Kahlers Disease)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals and Healthcare Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  2. Multiple Myeloma (Kahler's Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Multiple Myeloma (Kahler's Disease). A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Multiple Myeloma (Kahler's Disease). The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Multiple Myeloma (Kahler's Disease). While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturersacross the globe coveringDrug Master FilingsofUS, Europe and API Manufacturers in Asia specifically China and India. The researchanalysis also presents the global sales forecasts data till 2016. Browse Complete Report – http://www.aarkstore.com/pharmaceuticals-healthcare/97800/multiple-myeloma-kahlers-disease-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2015

  3. Data Sources • The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. • Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. • Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. .

  4. Scope • A snapshot of the global Market therapeutics scenario for Multiple Myeloma (Kahler's Disease). • A review of the marketed products under prescription for Multiple Myeloma (Kahler's Disease), regulatory information and marketing status. • Coverage of global patent coverage and detailed commentaries on the US patent challenges. • Graphical representation of investigational products for patent expiry and market exclusivities across the globe. • Product profiles for marketed products for Multiple Myeloma (Kahler's Disease) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. • Coverage of API Manufacturers for Multiple Myeloma (Kahler's Disease) drugs in the United States, Europe and Asian Regions with location details. • Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Multiple Myeloma (Kahler's Disease) drugs.

  5. Reasons to buy • Evaluate the marketing status and exclusivity details of Multiple Myeloma (Kahler's Disease)key products to exploit opportunities for generic drug development opportunities. • Identify and understand important and diverse types of therapeutics under Phase III development for Multiple Myeloma (Kahler's Disease). • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Multiple Myeloma (Kahler's Disease). • API intelligence over marketed drugs forMultiple Myeloma (Kahler's Disease)and gaining primary intelligence over active ingredients manufacturers across the globe. • API intelligence over leading Phase III Pipeline drugs. • Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

  6. Table of Content • Indication Overview • Marketed Drugs • Marketed Details of Drugs by Application Type • Marketed Details of Drugs (NDA) by Marketing Status • Marketed Details of Drugs by Patent Expiration Timeline • Active Pharmaceutical Ingredient (API) Manufacturers Assessment • API Manufacturers by United States Drug Master File (US DMF) Status • API Manufacturers by US DMF Status (Drug Specific) • API Manufacturers in Europe by Country • API Manufacturers in India by State • API Manufacturers in China by Province • Marketed Details of Approved Drugs by Geography • Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs • API Manufacturers by US DMF Status (Drug Specific)

  7. List of Tables • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, Marketed Drugs by Application Type, 2015 • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015 • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, (Year), 2015 • Multiple Myeloma (Kahler's Disease) Marketed Drugs, API Manufacturers by US DMF Status, 2015 • Multiple Myeloma (Kahler's Disease) Marketed Drugs, US DMF Status Drug Specific (Number), 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, Europe by Country, 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, India by State, 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, China by Province, 2015

  8. List of Figures • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015 • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015 • Multiple Myeloma (Kahler's Disease) Therapeutic Market, US, (Year), 2015 • Multiple Myeloma (Kahler's Disease) Marketed Drugs, API Manufacturers by US DMF Status (%), 2015 • Multiple Myeloma (Kahler's Disease) Marketed Drugs, US DMF Status Drug Specific (Number), 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, Europe by Country, 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, India by State, 2015 • Multiple Myeloma (Kahler's Disease) Drugs, API Manufacturers, China by Province, 2015

  9. Related reports: • Skin Health Spa PLC - Strategic SWOT Analysis Review • Biovest International, Inc. (BVTIQ) - Strategic SWOT Analysis Review • Natco Pharma Limited (NATCOPHARM) - Financial and Strategic SWOT Analysis Review • AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review • XOMA Corporation (XOMA) - Financial and Strategic SWOT Analysis Review • Global Epinephrine Autoinjector Market 2015-2019 • Human Growth Hormone Market in the US 2015-2019 • Global Acute Coronary Syndrome (ACS) Market 2015-2019 • Global Automated External Defibrillator Market 2015-2019 • Global Gaucher Disease Market 2015-2019

  10. Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Published: Feb 2015 | 100 Pages Multiple Myeloma (Kahler's Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Multiple Myeloma (Kahler's Disease). Price

  11. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related